Wall Street bounces back as investors shrug off trade tensions
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Harry and Meghan surprised by King Charles' letter on their status
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Qualcomm to issue warrant to Amazon for up to 25M shares
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Nike (NKE) PT Raised to $100 at Susquehanna Ahead of 1Q Release
September 20, 2018 7:20 AM EDTSusquehanna analyst Sam Poser raised the price target on Nike (NYSE: NKE) to $100.00 (from $93.00) while maintaining a Positive rating ahead of the company's 1Q earnings report. Proprietary checks indicate that the momentum of Nike Sportswear (NSW) continues to accelerate. NSW footwear continues to... More
Marsh & McLennan (MMC) PT Lowered to $98 at Citi Following JLT Acquisition
September 20, 2018 7:14 AM EDTCiti analyst James Naklicki lowered the price target on Marsh & McLennan (NYSE: MMC) to $98.00 (from $100.00) while maintaining a Buy rating as the company acquires JLT. MMC is acquiring nearly $2 billion in revenue from the deal, which will increase the gap between MMC... More
Viking Therapeutic (VKTX) PT Raised to 'Street High' $28 at H.C. Wainwright
September 18, 2018 11:57 AM EDTH.C. Wainwright analyst Joseph Pantginis raised the price target on Viking Therapeutic (NASDAQ: VKTX) to a 'Street High' $28.00 (from $15.00) while maintaining a Buy rating.
The analsyt commented, "This morning, the highly anticipated VK2809 top-line data in non-alcoholic fatty liver disease (NAFLD) and... More
